NOVATO, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP) today announced that Ted Daley, President, will present an update on its investigational drug candidate, Cysteamine Bitartrate Delayed-Release Capsules (RP103), for the potential treatment of nephropathic cystinosis at the Cystinosis Research Foundation (“CRF”) Day of Hope Family Conference to be held from April 20-21. The presentation will include data from the Raptor’s Phase 3 clinical trial of RP103 for the potential treatment of cystinosis as well as a regulatory update. Mr. Daley’s presentation will take place at Balboa Bay Club in Newport Beach, California on Friday, April 20th at 11:30 a.m. Pacific Time.
